Heron Therapeutics

Latest news

• Heron Therapeutics Announces FDA Approval of Zynrelef Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures
  23 January 2024
• FDA Approves Aponvie (aprepitant) for the Prevention of Postoperative Nausea and Vomiting (PONV)
  16 September 2022
• Heron Therapeutics Announces FDA Approval of an Indication Expansion for Zynrelef for Postoperative Pain Management
  9 December 2021
• Heron Therapeutics Announces Submission of HTX-019 NDA for the Prevention of Postoperative Nausea and Vomiting to FDA
  18 November 2021
• FDA Approves Zynrelef (bupivacaine and meloxicam) for the Management of Postoperative Pain
  13 May 2021
• Heron Therapeutics Announces Publication of Results from EPOCH 1 Follow-On Study of HTX-011 in Patients Undergoing Bunionectomy Surgery
  21 January 2021
• Heron Therapeutics Resubmits New Drug Application to FDA for HTX-011 for the Treatment of Postoperative Pain
  13 November 2020
• Heron Therapeutics Receives Complete Response Letter for HTX-011 for the Management of Postoperative Pain
  29 June 2020
• Heron Therapeutics Announces FDA Extension of Review Period for NDA for HTX-011 for the Management of Postoperative Pain
  19 February 2020
• Heron Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for HTX-011 for Management of Postoperative Pain
  28 October 2019

Drugs Associated with Heron Therapeutics, Inc.

Heron Therapeutics, Inc. manufactures, markets and/or distributes more than 4 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.